Expression of cyclic GMP‐inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP
Open Access
- 1 December 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 125 (7) , 1501-1510
- https://doi.org/10.1038/sj.bjp.0702227
Abstract
A combination of pharmacological, molecular biological and biochemical approaches were used to investigate the differential expression of two cyclic GMP‐inhibited cyclic nucleotide phosphodiesterase genes (PDE3A and PDE3B) in the rat. RT–PCR using PDE3A‐ or PDE3B‐specific oligonucleotide primers allowed amplification of products encoding PDE3A (508 bp) or PDE3B (499 bp) sequences from several rat tissues (heart, aorta, liver, kidney and epididymal fat), from primary cultures of aortic vascular smooth muscle cells (VSMC) as well as from an SV40 large T‐antigen immortalized aortic VSMC line. Immunoblotting experiments with PDE3‐selective antisera allowed the detection of both PDE3A and PDE3B immunoreactive proteins in several rat tissues, including tissues of the cardiovascular system, in primary cultures of aortic VSMC and in an SV40 large T‐antigen immortalized aortic VSMC line. In all cases, PDE3A was expressed as a 120 kDa protein which was only detected in the cytosolic fraction. PDE3B was expressed as a 135 kDa protein and its expression was limited to the particulate fraction of all tissues and cells studied. Prolonged incubation of cultured aortic VSMC with agents that increase VSMC cyclic AMP (forskolin or 8‐bromo‐cyclic AMP) produced marked time‐dependent increases in PDE3 activity which correlated with increases in PDE3A and PDE3B RT–PCR signals and a marked increase in particulate PDE3 activity and PDE3B protein. The physiological, pharmacological and biochemical implications of these findings are discussed based on previous reports of the effects of PDE3 inhibitors in the cardiovascular system and the relevance of our findings are presented in the context of the development of PDE3A and/or PDE3B‐selective pharmacological agents. British Journal of Pharmacology (1998) 125, 1501–1510; doi:10.1038/sj.bjp.0702227Keywords
This publication has 36 references indexed in Scilit:
- Isolation and Characterization of PDE8A, a Novel Human cAMP-Specific PhosphodiesteraseBiochemical and Biophysical Research Communications, 1998
- Molecular Cloning and Chromosomal Assignment of the Human Homologue of the Rat cGMP-Inhibited Phosphodiesterase 1 (PDE3A)—A Gene Involved in Fat Metabolism Located at 11p15.1Genomics, 1996
- Differential expression of cGMP‐inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell linesFEBS Letters, 1996
- Isolation of vascular smooth muscle cell cultures with altered responsiveness to the antiproliferative effect of heparinJournal of Cellular Physiology, 1996
- Identification of the Site in the cGMP-inhibited Phosphodiesterase Phosphorylated in Adipocytes in Response to Insulin and IsoproterenolPublished by Elsevier ,1996
- Complexity and Diversity of Mammalian Adenylyl CyclasesAnnual Review of Pharmacology and Toxicology, 1996
- Salbutamol Up-regulates PDE4 Activity and Induces a Heterologous Desensitization of U937 Cells to Prostaglandin E2Published by Elsevier ,1995
- Cytosolic and Sarcoplasmic Reticulum-Associated Low Km, cGMP-Inhibited cAMP Phosphodiesterase in Mammalian MyocardiumBiochemical and Biophysical Research Communications, 1993
- Cultured smooth muscle approach in the study of hypertensionCanadian Journal of Physiology and Pharmacology, 1992
- Purification and characterization of a human platelet cyclic nucleotide phosphodiesteraseBiochemistry, 1984